Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.27
DYAX's Cash to Debt is ranked higher than
66% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. DYAX: 2.27 )
DYAX' s 10-Year Cash to Debt Range
Min: 0.27   Max: No Debt
Current: 2.27

Equity to Asset 0.49
DYAX's Equity to Asset is ranked higher than
62% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. DYAX: 0.49 )
DYAX' s 10-Year Equity to Asset Range
Min: -1.26   Max: 0.82
Current: 0.49

-1.26
0.82
F-Score: 4
Z-Score: 5.83
M-Score: -2.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -9.84
DYAX's Operating margin (%) is ranked higher than
78% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. DYAX: -9.84 )
DYAX' s 10-Year Operating margin (%) Range
Min: -389.57   Max: -27.65
Current: -9.84

-389.57
-27.65
Net-margin (%) -26.34
DYAX's Net-margin (%) is ranked higher than
76% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. DYAX: -26.34 )
DYAX' s 10-Year Net-margin (%) Range
Min: -393.89   Max: -44
Current: -26.34

-393.89
-44
ROE (%) -16.44
DYAX's ROE (%) is ranked higher than
74% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. DYAX: -16.44 )
DYAX' s 10-Year ROE (%) Range
Min: -930.61   Max: -21.74
Current: -16.44

-930.61
-21.74
ROA (%) -8.11
DYAX's ROA (%) is ranked higher than
77% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. DYAX: -8.11 )
DYAX' s 10-Year ROA (%) Range
Min: -96.32   Max: -10.42
Current: -8.11

-96.32
-10.42
ROC (Joel Greenblatt) (%) -135.19
DYAX's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. DYAX: -135.19 )
DYAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1541.42   Max: -138.92
Current: -135.19

-1541.42
-138.92
Revenue Growth (%) -3.10
DYAX's Revenue Growth (%) is ranked higher than
74% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. DYAX: -3.10 )
DYAX' s 10-Year Revenue Growth (%) Range
Min: -37.4   Max: 21.1
Current: -3.1

-37.4
21.1
EBITDA Growth (%) 7.70
DYAX's EBITDA Growth (%) is ranked higher than
82% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. DYAX: 7.70 )
DYAX' s 10-Year EBITDA Growth (%) Range
Min: -49.1   Max: 10.4
Current: 7.7

-49.1
10.4
» DYAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

DYAX Guru Trades in Q3 2013

Jim Simons 94,400 sh (New)
PRIMECAP Management 10,906,990 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 1,059,000 sh (-26.15%)
» More
Q4 2013

DYAX Guru Trades in Q4 2013

Paul Tudor Jones 54,343 sh (New)
Jim Simons 528,000 sh (+459.32%)
PRIMECAP Management 11,806,990 sh (+8.25%)
Chuck Royce 809,000 sh (-23.61%)
» More
Q1 2014

DYAX Guru Trades in Q1 2014

Louis Moore Bacon 75,000 sh (New)
Steven Cohen 960,155 sh (New)
Jim Simons 742,804 sh (+40.68%)
PRIMECAP Management 11,806,990 sh (unchged)
Chuck Royce 485,600 sh (-39.98%)
Paul Tudor Jones 16,099 sh (-70.38%)
» More
Q2 2014

DYAX Guru Trades in Q2 2014

Joel Greenblatt 46,505 sh (New)
Steven Cohen 44,100 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
PRIMECAP Management 11,129,830 sh (-5.74%)
Chuck Royce 380,200 sh (-21.71%)
Jim Simons 469,186 sh (-36.84%)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.01%$6.11 - $9.96 $ 10.640%46505
PRIMECAP Management 2013-06-30 Add 24.89%0.01%$2.29 - $4.42 $ 10.6225%10906810
PRIMECAP Management 2012-09-30 New Buy0.04%$2.13 - $2.75 $ 10.6327%8732900
PRIMECAP Management 2012-06-30 Sold Out 0.02%$1.48 - $2.19 $ 10.6509%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.95
DYAX's P/B is ranked higher than
62% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. DYAX: 13.95 )
DYAX' s 10-Year P/B Range
Min: 2.05   Max: 74.67
Current: 13.95

2.05
74.67
P/S 20.04
DYAX's P/S is ranked higher than
73% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. DYAX: 20.04 )
DYAX' s 10-Year P/S Range
Min: 2.46   Max: 21.33
Current: 20.04

2.46
21.33
EV-to-EBIT -211.99
DYAX's EV-to-EBIT is ranked higher than
83% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. DYAX: -211.99 )
DYAX' s 10-Year EV-to-EBIT Range
Min: 13.7   Max: 87.5
Current: -211.99

13.7
87.5
Current Ratio 12.60
DYAX's Current Ratio is ranked higher than
91% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. DYAX: 12.60 )
DYAX' s 10-Year Current Ratio Range
Min: 1.34   Max: 13.3
Current: 12.6

1.34
13.3
Quick Ratio 12.39
DYAX's Quick Ratio is ranked higher than
91% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. DYAX: 12.39 )
DYAX' s 10-Year Quick Ratio Range
Min: 1.34   Max: 13.1
Current: 12.39

1.34
13.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.67
DYAX's Price/Net Cash is ranked higher than
82% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. DYAX: 17.67 )
DYAX' s 10-Year Price/Net Cash Range
Min: 3.14   Max: 251.17
Current: 17.67

3.14
251.17
Price/Net Current Asset Value 16.56
DYAX's Price/Net Current Asset Value is ranked higher than
81% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. DYAX: 16.56 )
DYAX' s 10-Year Price/Net Current Asset Value Range
Min: 2.76   Max: 237
Current: 16.56

2.76
237
Price/Tangible Book 13.95
DYAX's Price/Tangible Book is ranked higher than
68% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. DYAX: 13.95 )
DYAX' s 10-Year Price/Tangible Book Range
Min: 1.05   Max: 72
Current: 13.95

1.05
72
Price/Median PS Value 2.64
DYAX's Price/Median PS Value is ranked higher than
70% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. DYAX: 2.64 )
DYAX' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 4.21
Current: 2.64

0.15
4.21
Forward Rate of Return (Yacktman) -26.31
DYAX's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. DYAX: -26.31 )
DYAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -88.3   Max: -15.4
Current: -26.31

-88.3
-15.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DY8.Germany
Dyax Corp. is incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. The company a biopharmaceutical company with two business elements: Plasma Kallikrein-Mediated Angioedema Portfolio - The principal focus of its efforts is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE) and angioedema of unknown origin, or idiopathic angioedema. It developed KALBITOR (ecallantide) on its own and since February 2010, it has been selling it in the United States for the treatment of acute attacks of HAE; and Phage Display Licensing and Funded Research Program- leverage its proprietary phage display technology through Licensing and Funded Research Program, referred to as the LFRP. This program has provided the company a portfolio of product candidates being developed by licensees, which currently includes 13 product candidates in clinical development, including four products in Phase 3 trials. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. Using phage display technology, it developed ecallantide, a compound shown in vitro to be a high affinity, high specificity inhibitor of human plasma kallikrein. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR, are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for DYAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: DYAX, IBI, FARM, TAP, DBM Mar 19 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. Reports Operating Results (10-K) Mar 02 2011 
Dyax Corp. Reports Operating Results (10-Q) Nov 02 2010 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares Sep 15 2010 
Dyax Corp. (DYAX) CFO George V Migausky buys 12,000 Shares Aug 25 2010 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Weekly CFO Buy Highlights: F.N.B. Corp, Great Wolf Resorts Inc, Dyax Corp, Transcat Inc, Cal Dive In Jun 20 2009 
Dyax Corp. (DYAX) CFO George V Migausky buys 9,000 Shares Jun 16 2009 

More From Other Websites
Dyax Corp. Announces Issuance of Two Key U.S. Patents for DX-2930 Sep 15 2014
DYAX CORP Financials Aug 08 2014
DYAX CORP Files SEC form 10-Q, Quarterly Report Aug 01 2014
DYAX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 29 2014
Dyax Corp. Announces Second Quarter 2014 Financial Results Jul 29 2014
Q2 2014 Dyax Corp. Earnings Release - Time Not Supplied Jul 29 2014
Dyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed Journals Jul 23 2014
Dyax Corp. to Host Second Quarter 2014 Earnings Call and Webcast Jul 15 2014
Today's Perilous Reversal Stock: Dyax (DYAX) Jun 30 2014
Dyax Corp. (DYAX) Soars: Stock Rises 12.5% Jun 30 2014
Dyax Corp. to Participate in the 2014 Wells Fargo Healthcare Conference Jun 10 2014
Dyax Corp. to Participate in the Jefferies Global Healthcare Conference May 29 2014
UPDATE: Bank Of America Reiterates On Dyax On Positive Competitor Data May 28 2014
Dyax announces dosing of first subject in DX-2930 Phase 1b Trial May 28 2014
Dyax Corp. Announces Dosing of First Subject in Phase 1b Trial of DX-2930 in Patients with... May 28 2014
Dyax Corp. (DYAX) Soars: Stock Rises 27.4% May 28 2014
Why Dyax (DYAX) Stock Is Soaring Today May 27 2014
Dyax surges after data announced for competing HAE drug May 27 2014
BioCryst data has favorable read through for Dyax, says Jefferies May 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK